Get the Stockscreener App
11.20
2.38%
0.26
After Hours:
11.23
0.03
+0.27%
Avita Medical Inc stock is traded at $11.20, with a volume of 301.60K.
It is up +2.38% in the last 24 hours and up +141.90% over the past month.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
See More
Previous Close:
$10.94
Open:
$10.99
24h Volume:
301.60K
Relative Volume:
0.67
Market Cap:
$346.38M
Revenue:
$72.35M
Net Income/Loss:
$-45.34M
P/E Ratio:
-7.1315
EPS:
-1.5705
Net Cash Flow:
$-32.43M
1W Performance:
+8.21%
1M Performance:
+141.90%
6M Performance:
+125.81%
1Y Performance:
+161.07%
1-Day Range:
$10.80
$11.39
1-Week Range:
$9.84
$11.39
52-Week Range:
$3.22
$11.39
Avita Medical Inc Stock (RCEL) Company Profile
Name
Avita Medical Inc
Sector
Industry
Phone
661-568-1317
Address
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
11.20 | 312.05M | 72.35M | -45.34M | -32.43M | -1.5705 |
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Initiated | Northland Capital | Outperform |
| Nov-20-25 | Upgrade | BTIG Research | Sell → Neutral |
| Aug-08-25 | Downgrade | BTIG Research | Neutral → Sell |
| Dec-24-24 | Initiated | D. Boral Capital | Buy |
| Apr-11-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-27-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-21 | Initiated | Piper Sandler | Overweight |
| Aug-27-20 | Initiated | BofA Securities | Buy |
| Apr-21-20 | Initiated | Oppenheimer | Outperform |
| Mar-03-20 | Initiated | BTIG Research | Buy |
View All
Avita Medical Inc Stock (RCEL) Latest News
Precision Trading with Avita Medical Inc. (RCEL) Risk Zones - news.stocktradersdaily.com
564,952 Shares in Avita Medical Inc. $RCEL Bought by BlackRock Inc. - MarketBeat
RCEL stock gains on fresh price data while Avita Medical readies next steps - AD HOC NEWS
Gross margin % of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - TradingView
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference - investingnews.com
AVITA Medical to Showcase Leadership at Lake Street and Morgan Stanley Healthcare Conferences in September 2026 - Kalkine Media
AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs Balance Sheet – HAM:51KB - TradingView
51KB Stock Price and Chart — HAM:51KB - TradingView
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy - Yahoo Finance
Avita Medical Inc.ADR Peer Comparison – Compare with Others - Value Research
Lake Street Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $12 - Moomoo
RCEL | Avita Medical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases - Yahoo Finance
AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL) - Seeking Alpha
Avita Medical (RCEL) Stock Forum and Discussion - Moomoo
RCEL Maintained by TD Cowen -- Price Target Raised to $14.00 - GuruFocus
TD Cowen raises Avita Medical stock price target on PermeaDerm data - Investing.com Canada
RCEL Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
AVITA Medical (NASDAQ:RCEL) Raises Full-Year Guidance on Spray-On Skin Adoption - Kalkine Media
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BTIG raises Avita Medical stock price target on positive trial data - Investing.com Canada
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $14 - Moomoo
AVITA Medical Reveals PermeaDerm Trial Results: 70% Cost Reduction Compared to Allograft - Kalkine Media
Avita Medical Inc. (NASDAQ:RCEL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
AVITA Medical (ASX:AVH) Jumps 23.18% as Shares Extend a 67% One-Year Recovery - Kalkine
AVITA Medical (ASX:AVH) Soars 22.73% as Revenue Upgrade and Cash-Flow Target Reset the Conversation - Kalkine
AVITA Medical (ASX: AVH) Reports 70% Cost Advantage for PermeaDerm in Randomized Study - Kalkine
Avita Medical Says Clinical Study for Biosynthetic Wound Matrix Meets Primary Endpoint - marketscreener.com
AVITA Medical's PermeaDerm-I Study Reveals 70% Cost Savings Over Cadaveric Allograft with Equivalent Clinical Results - Kalkine Media
AVITA Medical Inc to Host Key Opinion Leader Webinar Transcript - GuruFocus
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes - Investing News Network
RCEL Looks 21.8% Undervalued on GF Value™ - GuruFocus
Avita Medical Says PermeaDerm Study Meets Primary Endpoint, Showing 70% Cost Reduction - marketscreener.com
AVITA Medical’s PermeaDerm shows 70% cost savings over allograft By Investing.com - Investing.com Canada
A wound matrix cut prep time 96% with outcomes comparable to cadaver grafts - Stock Titan
Avita Medical Raises Full Year 2026 Revenue Guidance - sekbernews.id
Avita Medical Raises Revenue Guidance and Targets Breakeven - sekbernews.id
AVITA Medical Inc Annual Shareholders Meeting Transcript - GuruFocus
RCEL Q2 2026 Earnings: Narrower Quarterly Loss Beats Estimates; Shares Slip 2%Earnings Quality Analysis - Vinanet
AVITA Medical, Inc. (RCEL) Shareholder/Analyst CallSlideshow (NASDAQ:RCEL) 2026-08-16 - Seeking Alpha
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18% - MarketBeat
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds - MarketBeat
RCEL Q2 2026 Earnings: EPS Beat of 14.5% Overshadowed by a 2% Stock DeclineEarnings Expansion Phase - Vinanet
RCEL Q2 2026 Earnings: Loss Narrower Than Expected, Delivering 14.5% EPS SurpriseSpecial Dividend Alert - Vinanet
RCEL Q2 2026 Earnings: Narrower Loss Beats Expectations as Shares Edge LowerEstimate Revision Count - Vinanet
AVITA Medical Inc (RCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript - AOL.com
Avita Medical (RCEL) Rises 3.57% as Shares Rebound Toward Key ResistanceStock Surge Alerts - vinanet.vn
Avita Medical (RCEL) Dips to $8.12 as Support at $7.71 Moves into FocusPCR Extreme - vinanet.vn
Avita Medical Inc. (ASX:AVH) Share Price Remains Unchanged as Stock Trades Within Daily Range - Kalkine
Avita Medical Inc Stock (RCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avita Medical Inc Stock (RCEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Woody Joseph Fralin | Director |
Jun 09 '26 |
Buy |
4.19 |
10,000 |
41,900 |
102,761 |
| Woody Joseph Fralin | Director |
Jun 03 '26 |
Buy |
4.09 |
10,000 |
40,949 |
92,761 |
| Woody Joseph Fralin | Director |
Jun 01 '26 |
Buy |
4.30 |
10,000 |
43,000 |
10,000 |
| Woody Joseph Fralin | Director |
Jun 02 '26 |
Buy |
4.19 |
10,000 |
41,936 |
20,000 |
| O'Toole David D | CFO |
May 20 '26 |
Buy |
4.26 |
2,000 |
8,520 |
145,927 |
| O'Toole David D | CFO |
May 19 '26 |
Buy |
4.24 |
2,000 |
8,480 |
143,927 |
| O'Toole David D | CFO |
Feb 19 '26 |
Buy |
4.15 |
3,000 |
12,450 |
140,127 |
0.86%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):